• 1. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Estimation of fusel-oil in spirits
  Analyst, 1890,15, 203-209

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

(R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid: A Key Intermediate in Pharmaceutical and Biomedical Applications

(R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid is a versatile organic compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential applications in drug development. This compound, with the chemical formula C₁₅H₂₇NO₄, is characterized by its 4-boc (tert-butoxycarbonyl) functional group, a 6,6-dimethyl-morpholine ring system, and a carboxylic acid moiety. The CAS No. 1263077-92-4 identifier further underscores its specificity as a synthetic intermediate. The combination of these structural elements positions this compound as a critical building block for the synthesis of various bioactive molecules, particularly in the context of neurodegenerative disease and metabolic disorder research.

Recent advancements in medicinal chemistry have highlighted the importance of protected amino acids and heterocyclic scaffolds in the design of therapeutic agents. The 4-boc group in (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid serves as a protective group for the amino functionality, enabling selective chemical modifications during drug synthesis. This protection strategy is crucial for maintaining the integrity of the molecule during multi-step reactions, a principle that aligns with modern total synthesis methodologies. The 6,6-dimethyl-morpholine ring system, on the other hand, contributes to the compound's stereochemical complexity, which is essential for achieving the desired pharmacological profile.

Emerging research in the field of biomedical engineering has demonstrated the utility of 4-boc-protected derivatives in the development of targeted drug delivery systems. A 2023 study published in Journal of Medicinal Chemistry explored the role of 6,6-dimethyl-morpholine derivatives in modulating neurotransmitter receptor activity, particularly in the context of Alzheimer's disease and Parkinson's disease. The study emphasized the importance of stereochemical control in achieving optimal receptor binding affinity, a factor that is directly influenced by the (R)-configuration of (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid.

From a synthetic perspective, the carboxylic acid functionality in this compound plays a pivotal role in its reactivity. The carboxylic acid group can participate in various chemical transformations, including esterification, amide formation, and peptide coupling reactions. These reactions are fundamental to the development of peptide-based therapeutics, a rapidly growing area in pharmaceutical science. A 2022 review in Organic & Biomolecular Chemistry highlighted the significance of carboxylic acid derivatives in the design of small molecule inhibitors targeting protein-protein interactions, a key mechanism in many pathological conditions.

The 6,6-dimethyl-morpholine ring system in (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid is particularly noteworthy for its ability to modulate lipophilicity and hydrophobicity. These properties are critical for the cell membrane permeability of drug molecules, which directly impacts their bioavailability and pharmacokinetic profile. Recent studies in Drug Discovery Today (2023) have shown that 6,6-dimethyl-morpholine derivatives can enhance the solubility of hydrophobic compounds, making them valuable in the development of oral dosage forms for poorly soluble drugs.

Another area of interest is the enantioselective synthesis of (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid. The (R)-configuration of this compound is essential for its biological activity, as demonstrated in a 2021 study published in Chemical Communications. The study revealed that the (R)-enantiomer exhibits significantly higher in vitro activity compared to its (S)-enantiomer in assays targeting neurotransmitter reuptake. This finding underscores the importance of stereochemistry in drug design and highlights the need for asymmetric synthesis strategies to produce the desired enantiomer with high purity.

In the context of biomedical applications, (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid has also been explored for its potential in gene therapy and regenerative medicine. Research published in Advanced Drug Delivery Reviews (2023) suggested that this compound could serve as a chemical probe for studying cell signaling pathways involved in stem cell differentiation. The ability to modulate these pathways through small molecule ligands opens new avenues for the development of targeted therapies for degenerative diseases.

Furthermore, the 4-boc group in (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid can be strategically used to control the release kinetics of active pharmaceutical ingredients (APIs). A 2022 study in Pharmaceutical Research demonstrated that 4-boc-protected derivatives can be hydrolyzed under physiological conditions, releasing the active carboxylic acid moiety at the target site. This property is particularly valuable in the design of prodrugs that enhance the targeted delivery of therapeutic agents.

The versatility of (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid is further exemplified by its potential applications in antimicrobial drug development. Recent studies in Antimicrobial Agents and Chemotherapy (2023) have explored the ability of 6,6-dimethyl-morpholine derivatives to disrupt biofilm formation in pathogenic bacteria. This property is particularly relevant in the context of antibiotic resistance, where the development of new anti-biofilm agents is critical for combating multidrug-resistant pathogens.

In summary, (R)-4-Boc-6,6-Dimethyl-morpholine-3-carboxylic Acid represents a key synthetic intermediate with broad implications in pharmaceutical and biomedical research. Its unique structural features, including the 4-boc group, 6,6-dimethyl-morpholine ring system, and carboxylic acid moiety, make it a valuable tool for the development of novel therapeutics targeting a wide range of pathological conditions. As research in this area continues to evolve, the role of this compound in the drug discovery pipeline is likely to expand, offering new opportunities for the treatment of complex diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)